Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Crinetics Pharmaceuticals...

    NASDAQ: CRNX · Real-Time Price · USD
    31.07
    -0.70 (-2.20%)
    At close: Jun 16, 2025, 3:59 PM
    31.50
    1.38%
    After-hours: Jun 16, 2025, 05:24 PM EDT

    Crinetics Pharmaceuticals Statistics

    Share Statistics

    Crinetics Pharmaceuticals has 93.68M shares outstanding. The number of shares has increased by 17.99% in one year.

    Shares Outstanding

    n/a
    		 93.68M

    Shares Change (YoY)

    n/a
    		 17.99%

    Shares Change (QoQ)

    n/a
    		 0.34%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 86.71M

    Failed to Deliver (FTD) Shares

    n/a
    		 44

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 10.21M, so 10.9% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 10.21M

    Short % of Shares Out

    n/a
    		 10.9%

    Short % of Float

    n/a
    		 12.41%

    Short Ratio (days to cover)

    n/a
    		 11.56

    Valuation Ratios

    The PE ratio is -13.84 and the forward PE ratio is -6.77. Crinetics Pharmaceuticals's PEG ratio is 0.

    PE Ratio

    n/a
    		 -13.84

    Forward PE

    n/a
    		 -6.77

    PS Ratio

    n/a
    		 3975.39

    Forward PS

    n/a
    		 2.5

    PB Ratio

    n/a
    		 3.12

    P/FCF Ratio

    n/a
    		 -17.97

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Crinetics Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 23.04, with a Debt / Equity ratio of 0.04.

    Current Ratio

    n/a
    		 23.04

    Quick Ratio

    n/a
    		 23.04

    Debt / Equity

    n/a
    		 0.04

    Debt / EBITDA

    n/a
    		 -0.15

    Debt / FCF

    n/a
    		 -0.23

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $2,377.57

    Profits Per Employee

    n/a
    		 $-682,855.84

    Employee Count

    n/a
    		 437

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -30.51% in the last 52 weeks. The beta is 0.28, so Crinetics Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.28

    52-Week Price Change

    n/a
    		 -30.51%

    50-Day Moving Average

    n/a
    		 31.05

    200-Day Moving Average

    n/a
    		 43.3

    Relative Strength Index (RSI)

    n/a
    		 46.96

    Average Volume (20 Days)

    n/a
    		 945,357

    Income Statement

    In the last 12 months, Crinetics Pharmaceuticals had revenue of 1.04M and earned -298.41M in profits. Earnings per share was -3.69.

    Revenue

    n/a
    		 1.04M

    Gross Profit

    n/a
    		 -1.75M

    Operating Income

    n/a
    		 -338.85M

    Net Income

    n/a
    		 -298.41M

    EBITDA

    n/a
    		 -338.85M

    EBIT

    n/a
    		 -338.85M

    Earnings Per Share (EPS)

    n/a
    		 -3.69
    Full Income Statement

    Balance Sheet

    The company has 264.55M in cash and 51.72M in debt, giving a net cash position of 212.82M.

    Cash & Cash Equivalents

    n/a
    		 264.55M

    Total Debt

    n/a
    		 51.72M

    Net Cash

    n/a
    		 212.82M

    Retained Earnings

    n/a
    		 -952.11M

    Total Assets

    n/a
    		 1.36B

    Working Capital

    n/a
    		 1.23B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -225.97M and capital expenditures -3.84M, giving a free cash flow of -229.81M.

    Operating Cash Flow

    n/a
    		 -225.97M

    Capital Expenditures

    n/a
    		 -3.84M

    Free Cash Flow

    n/a
    		 -229.81M

    FCF Per Share

    n/a
    		 -2.84
    Full Cash Flow Statement

    Margins

    Gross margin is -168.05%, with operating and profit margins of -32613.47% and -28720.69%.

    Gross Margin

    n/a
    		 -168.05%

    Operating Margin

    n/a
    		 -32613.47%

    Pretax Margin

    n/a
    		 -28720.69%

    Profit Margin

    n/a
    		 -28720.69%

    EBITDA Margin

    n/a
    		 -32613.47%

    EBIT Margin

    n/a
    		 -32613.47%

    FCF Margin

    n/a
    		 -22118.77%

    Dividends & Yields

    CRNX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CRNX is $77.5, which is 149.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $77.5

    Price Target Difference

    n/a
    		 149.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 11
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 14.76

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist